Alton Oliver Sartor, Scott T. Tagawa, Nat Lenzo, David Cade, Neeraj Agarwal. "ProstACT GLOBAL: A phase 3 study of
            <sup>177</sup>
            Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.5_suppl.tps303